Component

Human whole-blood coagulability measured by thromboelastography

Species, preparation, dose and limitations are retained on linked claims.

1 recorded relationships. Experimental role, claim status and evidence remain attached to each record.

How nutrients influence it

Every nutrient with a recorded effect on this component, credited to the nutrient that acted rather than the chapter that recorded it. Open a nutrient to see the findings and the conditions they were measured under.

How nutrients reach it in more than one step

Chains of two or more recorded steps that end here, grouped by the nutrient they start from. Each step is a separate finding, so a chain is a route a mechanism could take, not proof that it does.

Tracing routes…

What it does

Every recorded relationship this component is part of, grouped by its role. Plain wording comes first; the technical statement follows.

Recorded relationships

What acts on it

  1. Adding bromelain ex vivo reduced coagulability, prolonged PT/APTT, and reduced ADP-induced platelet aggregation in human blood samples.

    Experimental context and source evidence
    dose
    Bromelain 0.4 U/mL
    duration
    Acute
    evidence_access
    Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    evidence_scope
    literature_reviewed; model-specific source-derived curation
    experimental_model
    Human normal and hypercoagulable blood samples
    limitations
    Neither oral nor intravenous exposure was tested; the small mouse experiment showed a nonsignificant trend toward hypercoagulability after intraperitoneal dosing.
    nutrient_topic
    Bromelain chapter; interacting nutrients, drugs, peptides and proteins retain their experimental settings. · Bromelain
    organism
    Human normal and hypercoagulable blood samples
    plain_language
    Adding bromelain ex vivo reduced coagulability, prolonged PT/APTT, and reduced ADP-induced platelet aggregation in human blood samples.
    primary_references
    Bromelain has paradoxical effects on blood coagulability: a study using thromboelastography. (2016). https://pubmed.ncbi.nlm.nih.gov/25517253/ DOI: 10.1097/MBC.0000000000000244
    route
    Ex vivo addition
    tissue
    Thromboelastography, PT, APTT and platelet aggregation

    Bromelain: mechanism of action and interactions (2026-09-20) · lines 110–119

    Original AI-assisted source-specific curation with primary-study citations, model, exposure, route, duration, negative findings and limitations preserved. Not publisher full text. · supports · Human normal and hypercoagulable blood samples · source_derived_draft · unverified_draft

    ## bromelain-exvivo-coagulation Adding bromelain ex vivo reduced coagulability, prolonged PT/APTT, and reduced ADP-induced platelet aggregation in human blood samples. Model/species: Human normal and hypercoagulable blood samples Tissue/system: Thromboelastography, PT, APTT and platelet aggregation Exposure: Bromelain 0.4 U/mL Route: Ex vivo addition Duration: Acute Limits: Neither oral nor intravenous exposure was tested; the small mouse experiment showed a nonsignificant trend toward hypercoagulability after intraperitoneal dosing. Primary reference: Bromelain has paradoxical effects on blood coagulability: a study using thromboelastography. (2016). https://pubmed.ncbi.nlm.nih.gov/25517253/ DOI: 10.1097/MBC.0000000000000244 Access: Primary PubMed abstract and indexed metadata reviewed. Full-text method details not stated here remain unresolved.
    Complete structured claim and evidence

In the sources

Preserved passages that mention this component, quoted exactly. Open one to read it in context.

    This is a research prototype built from draft material. It is not medical advice, and its statements still await verification against the original studies.

    Evidence, AI assistance and curation standards